Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Comprehensive docking and refinement of human glutaminyl cyclase inhibitors for the drug discovery of alzheimer’s disease
- At: Seoul (South Korea) (2017)
- Type: Poster
- By: CHOI, Sun (Ewha Womans University, Korea, Republic Of)
- Co-author(s): Sun Choi:
Minghua Cui: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea, Republic Of
Jongmi Park: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea, Republic Of
Jeewoo Lee: College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of
BackgroundGlutaminyl cyclase (QC) is an enzyme catalyzing the N-terminal modification of glutamyl or glutaminyl precursors into pyroglutamate. The formation of pyroglutamate-modified Aβ peptide triggers the accumulation of Aβ oligomer and proto-fibrils causing neurotoxicity like brain cell death.
PurposeSince these toxic materials aggravate.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019